Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -14.69% is 73% above its 5-year average of -54.07%, near the high end of its 5-year range (-315.92%–-5.81%).
As of the fiscal period ended Tuesday, March 31, 2026. 22.48% below its 12-month average of -11.99%.
Reported quarterly EBITDA margin; no daily interpolation.
EBITDA MARGIN
-14.69%
EBITDA MARGIN AVG TTM
-11.99%
EBITDA MARGIN AVG 3Y
-21.58%
EBITDA MARGIN AVG 5Y
-38.66%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-22.48%
CURRENT VS 3Y AVG
+31.92%
CURRENT VS 5Y AVG
+62.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Tempus AI, Inc.
Market Cap
$7.43B
EBITDA Margin
-14.69%
TTM Avg
-11.99%
3Y Avg
-21.58%
5Y Avg
-38.66%
Market Cap
$8.01B
EBITDA Margin
-3.14%
TTM Avg
-1.08%
3Y Avg
-5.02%
5Y Avg
-19.32%
Market Cap
$8.85B
EBITDA Margin
18.42%
TTM Avg
17.41%
3Y Avg
19.12%
5Y Avg
20.05%
Market Cap
$5.76B
EBITDA Margin
6.82%
TTM Avg
6.08%
3Y Avg
-0.44%
5Y Avg
-8.67%
Market Cap
$10.27B
EBITDA Margin
15.05%
TTM Avg
14.69%
3Y Avg
13.35%
5Y Avg
14.10%
Market Cap
$10.37B
EBITDA Margin
-7.87%
TTM Avg
-5.60%
3Y Avg
-1.35%
5Y Avg
0.44%
Market Cap
$10.45B
EBITDA Margin
2.15%
TTM Avg
3.41%
3Y Avg
4.20%
5Y Avg
4.49%
Market Cap
$11.29B
EBITDA Margin
17.40%
TTM Avg
22.43%
3Y Avg
29.14%
5Y Avg
30.66%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tempus AI, Inc. (TEM) | $7.43B | -14.69% | -11.99% | -21.58% | -38.66% |
| Oscar Health, Inc. (OSCR)vs › | $8.01B | -3.14% | -1.08% | -5.02% | -19.32% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $8.85B | 18.42% | 17.41% | 19.12% | 20.05% |
| Hims & Hers Health, Inc. (HIMS)vs › | $5.76B | 6.82% | 6.08% | -0.44% | -8.67% |
| Henry Schein, Inc. (HSIC)vs › | $9.83B | 8.11% | 8.11% | 8.28% | 8.19% |
| Universal Health Services, Inc. (UHS)vs › | $10.27B | 15.05% | 14.69% | 13.35% | 14.10% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -7.87% | -5.60% | -1.35% | 0.44% |
| Molina Healthcare, Inc. (MOH)vs › | $10.45B | 2.15% | 3.41% | 4.20% | 4.49% |
| Bio-Techne Corporation (TECH)vs › | $11.29B | 17.40% | 22.43% | 29.14% | 30.66% |
| Charles River Laboratories International, Inc. (CRL)vs › | $11.44B | 22.69% | 18.62% | 20.95% | 21.80% |
Gross Margin
69.5%
EBITDA Margin
-14.7%
Operating Margin
-18.1%
Net Margin
-22.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-03-31 | -14.69% |
| 2025-12-31 | -5.81% |
| 2025-09-30 | -9.85% |
| 2025-06-30 | -10.72% |
| 2025-03-31 | -18.90% |
| 2024-12-31 | -20.55% |
| 2024-09-30 | -24.42% |
| 2024-06-30 | -315.92% |
| 2024-03-31 | -30.23% |
| 2023-12-31 | -29.62% |
| 2023-09-30 | -26.73% |
| 2023-06-30 | -27.80% |
| 2023-03-31 | -39.63% |
| 2022-12-31 | -49.83% |
| 2021-12-31 | -66.93% |
| 2021-09-30 | -111.79% |
| 2021-06-30 | -84.89% |
| 2021-03-31 | -84.89% |
| 2020-12-31 | -35.73% |
| 2020-09-30 | -91.73% |
| 2020-06-30 | -241.17% |
| 2020-03-31 | -241.17% |
